NOVAVAX INC cotiza a 12.66 USD y tiene una capitalización bursátil de $2.1B. En los últimos 12 meses ha facturado $414M con un margen de flujo de caja libre del -22.3%. Datos fundamentales de la SEC EDGAR con hasta 20 años de histórico, insiders, institucionales y valoración DCF.Más empresas del sector Salud
Novavax, Inc., a biotechnology company, engages in the discovery, development, and commercialization of vaccines to prevent serious infectious diseases in the United States, Europe, and internationally. The company commercializes Nuvaxovid, a COVID-19 vaccine; and R21 Matrix-M adjuvant malaria vaccine. It has license a…
| Periodo | 2026-11 | 2026-08 | 2026-05 | 2026-02 |
|---|---|---|---|---|
| Real | — | $-0.32 | $-0.06 | $0.11 |
| Estimado | $-0.16 | $-0.38 | $-0.37 | $-0.55 |
| Sorpresa | — | +15.8% | +83.8% | +120.0% |
| Métrica | NVAX | Mediana Sector | Δ |
|---|---|---|---|
| Gross Margin | 93.5% | 57.0% | +36.5% |
| Operating Margin | 40.3% | -38.6% | +78.9% |
| Net Margin | 39.2% | -33.6% | +72.8% |
| FCF Margin | -22.3% | -13.9% | -8.4% |
| ROE | — | -40.4% | — |
| ROA | 37.4% | -32.0% | +69.4% |
| Current Ratio | 2.13 | 2.84 | -0.71 |
| Debt / Equity | — | 0.28 | — |